文献速递临床免疫质量管理与危急值

三种自动化降钙素原检测方法的多中心比对及室间质评材料互通性评价

Multicenter comparison of three automated procalcitonin (PCT) assays and commutability evaluation of EQA/PT materials.
PubMed 文献 · Clin Chim Acta · 2026-04-27

本研究验证了Kryptor BRAHMS PCT sensitive、Beckman Coulter DXI 800 Access PCT和Roche BRAHMS PCT三种PCT免疫分析法的定量下限/功能灵敏度与精密度,用506例临床血清样本进行方法比对,并评估四类EQA/PT材料的互通性。结果显示三种方法相关性高、临床一致性良好,但EQA/PT材料互通性普遍较差,其中冷冻混合人血清表现最佳。

要点

  • 三种PCT检测方法在0.1~10 μg/L阈值的临床一致性均超过95%。
  • 方法间相关性达0.994~0.998,相对偏倚在-13.9%~23.3%之间。
  • 四类EQA/PT材料互通性普遍较差,冷冻混合人血清相对最佳但仍不完全互通。

核心结论

  • 三种PCT免疫分析法均满足临床检测要求,方法间相关性高且临床一致性良好。
  • 所评价的四类EQA/PT材料互通性普遍较差,冷冻混合人血清是其中最适合的EQA/PT材料,但仍存在残余非互通性。

研究设计与样本

  • 多中心方法比对研究,依据CLSI EP17验证三种PCT检测方法的定量下限/功能灵敏度。
  • 依据CLSI EP15在0.5 μg/L和2 μg/L浓度验证精密度。
  • 使用506例来自个体患者的临床血清样本进行方法比对。
  • 使用17份EQA/PT材料(包括冷冻混合人血清、冻干材料、含重组PCT的牛血清白蛋白溶液和含重组PCT的人血清)与50例临床个体血清样本一起检测,采用偏倚差值法评价互通性。

主要发现

  • 三种方法的定量下限/功能灵敏度和不精密度均符合声称标准。
  • 两两比较相关性达0.994~0.998(均p < 0.0001),相对偏倚在-13.9%~23.3%之间。
  • 在0.1 μg/L、0.25 μg/L、0.5 μg/L、2.0 μg/L和10 μg/L阈值下,所有方法间临床一致性均超过95%。
  • 四类EQA/PT材料互通性普遍较差,可互通结果比例分别为:冻干材料6/18、牛血清白蛋白溶液1/15、人血清5/15、冷冻混合人血清7/12。
  • 冷冻混合人血清在所测材料中互通性最高。

关键数值与推荐

  • 方法比对相对偏倚范围为-13.9%~23.3%。
  • 0.1 μg/L、0.25 μg/L、0.5 μg/L、2.0 μg/L和10 μg/L阈值下临床一致性均超过95%。
  • EQA/PT材料可互通比例:冻干材料6/18、牛血清白蛋白溶液1/15、人血清5/15、冷冻混合人血清7/12。

临床怎么用

  • 检验科可依据本研究结果评估三种PCT检测方法在临床阈值附近的互换性。
  • 选择EQA/PT材料时需注意其互通性差异,冷冻混合人血清在同类材料中相对更适合。
  • 对EQA/PT结果的解读应考虑材料残余非互通性带来的偏倚。

局限性

  • 部分EQA/PT材料仍存在残余非互通性,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to assess the comparability of three commercial procalcitonin (PCT) immunoassays, including Kryptor BRAHMS PCT sensitive, Beckman Coulter DXI 800 Access PCT and Roche BRAHMS PCT, and to evaluate the commutability of four types of External Quality Assessment/Proficiency Tests (EQA/PT) materials among the three assays. METHODS: The limits of quantitation or functional sensitivity (LoQ/FS) for the three PCT assays were validated according to the CLSI EP17 guidelines. Precision was verified at 0.5 μg/L and 2 μg/L according to CLSI EP15 document. A method comparison study was conducted using 506 clinical serum samples from individual patients. Seventeen EQA/PT materials, including frozen pooled human serum (FFS), lyophilized materials (Lyo), bovine serum albumin solution (BSA) with recombinant PCT, and human serum (HS) with recombinant PCT, were tested together with 50 clinical individual serum samples. The commutability of EQA/PT materials was evaluated using the difference in bias approach. RESULTS: The LoQ/FS and imprecision of all three assays met the claimed standards. Pairwise comparisons demonstrated high correlations ranging from 0.994 to 0.998 (all p < 0.0001), with relative biases between -13.9% and 23.3%. Clinical consistency at thresholds of 0.1 μg/L, 0.25 μg/L, 0.5 μg/L, 2.0 μg/L, and 10 μg/L exceeded 95% across all methods. The commutability of the four EQA/PT material types was generally poor. The proportions of commutable results were 6/18 for Lyo, 1/15 for BSA, 5/15 for HS, and 7/12 for FFS, with FFS showing the highest commutability among the materials tested. CONCLUSIONS: The assays meet clinical requirements for PCT testing. Among the four EQA/PT materials evaluated, the HS, Lyo, and BSA materials demonstrated limited commutability. Although FFS does not exhibit full commutability, it is considered the most suitable EQA/PT material among those tested. Some residual non-commutability still exists and warrants further investigation.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Zeng J, Teng C, Li H, et al. Multicenter comparison of three automated procalcitonin (PCT) assays and commutability evaluation of EQA/PT materials. Clin Chim Acta. 2026. PMID: 42055310. doi:10.1016/j.cca.2026.121043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。